Variation in seizure prophylaxis in severe pediatric traumatic brain injury

Paige J Ostahowski1, Nithya Kannan2, Mark S Wainwright3

  • 1Medical Student Research Training Program, University of Washington School of Medicine.

Insights

Pediatric trauma centers show significant variation in seizure prophylaxis for severe traumatic brain injury (TBI). Fosphenytoin was common, but timing and drug choice differed widely, potentially impacting outcomes.

Area of Science:

  • Neurology
  • Trauma Surgery
  • Pediatric Critical Care

Background:

  • Posttraumatic seizures are a significant complication of severe traumatic brain injury (TBI).
  • Current practices for seizure prophylaxis in pediatric TBI patients exhibit considerable variability.
  • Understanding this variation is crucial for optimizing patient care and outcomes.

Purpose of the Study:

  • To investigate the variation in seizure prophylaxis selection and administration among pediatric trauma centers.
  • To identify factors associated with the use of seizure prophylaxis in severe pediatric TBI.
  • To analyze the timing and choice of medications used for seizure prophylaxis.

Main Methods:

  • Retrospective multicenter cohort study involving 236 children (<18 years) with severe TBI.
  • Data collected from 5 regional pediatric trauma centers between 2007 and 2011.
  • Analysis of seizure prophylaxis use, timing, and medication choice.

Main Results:

  • 187 (79%) of patients received seizure prophylaxis.
  • Fosphenytoin (47%) and phenytoin (40%) were the most common initial medications.
  • Significant variation existed in prophylaxis use (ranging from 0% to 100% across centers) and timing (63% within 24 hours, 50% prehospital/ED).
  • Prophylaxis use was associated with younger age, inflicted TBI, subdural hematoma, and cerebral infarction.

Conclusions:

  • There is substantial heterogeneity in seizure prophylaxis practices for severe pediatric TBI across trauma centers.
  • The observed variation in timing and medication choice may contribute to the lack of clear evidence on prophylaxis efficacy.
  • Standardization of seizure prophylaxis protocols in pediatric TBI may be warranted.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.0K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
426
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.2K